 Hutchmed China Ltd AIM:HCM, NASDAQ:HCM, HKG:0013 has moved higher after the start of new trials for a treatment for lung cancer. The phase 3 trial involves Hutchmeds orphathy savolitinib, an oral MET tyrosine kinase inhibitor TKI, in combination with AstraZenecas Tagrisso epidermal growth factor receptor. 